http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2008101383-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2006-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2008101383-A |
| titleOfInvention | A NEW COMBINATION OF ANTIMAdCAM ANTIBODY AND ANTI-FIBROUS CASPASE INHIBITOR FOR TREATMENT OF LIVER FIBROSIS |
| abstract | 1. The combination of a monoclonal antibody against MAdCAM or antigennegative part of the indicated antibodies with an antifibrotic agent. ! 2. The combination according to claim 1, where the antifibrotic agent is a caspase inhibitor. ! 3. The combination according to claim 2, where the caspase inhibitor is a compound of formula I! ! where A is a natural or unnatural amino acid of the formulas IIa-i! ! ! ! B represents a hydrogen atom, a deuterium atom, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl, 2-benzoxazolyl, substituted 2-oxazolyl, (CH2) n-cycloalkyl, (CH2) n-phenyl, (CH2) n - (substituted phenyl), (CH2) n- (1- or 2-naphthyl), (CH2) n- (substituted 1- or 2-naphthyl), (CH2) n- (heteroaryl), (CH2) n- ( substituted heteroaryl), halogenmethyl, CO2R12, CONR13R14, CH2ZR15, CH2OCO (aryl), CH2OCO (heteroaryl) or CH2OPO (R16) R17, where Z represents an oxygen or sulfur atom, or B represents a group of formulas IIIa-c! ! R1 represents alkyl, cycloalkyl, (cycloalkyl) alkyl, phenyl, substituted phenyl, phenylalkyl, substituted phenylalkyl, naphthyl, substituted naphthyl, (1- or 2-naphthyl) alkyl, substituted (1- or 2-naphthyl) alkyl, heteroaryl, substituted heteroaryl, (heteroaryl) alkyl, substituted (heteroaryl) alkyl, R1a (R1b) N or R1cO; and! R2 is hydrogen, lower alkyl, cycloalkyl, (cycloalkyl) alkyl, phenyl, substituted phenyl, phenylalkyl, substituted phenylalkyl, naphthyl, substituted naphthyl, (1- or 2-naphthyl) alkyl or substituted (1- or 2-naphthyl) alkyl ; and where ! R1a and R1b independently represent hydrogen, alkyl, cycloalkyl, (cycloalkyl) alkyl, phenyl, substituted phenyl, phenylalkyl, substituted phenylalkyl, naphthyl, substituted naphthyl, (1- or 2-naphthyl) alkyl, substituted (1- or 2-naphthyl ) alkyl, heteroaryl, substituted heteroaryl, (heteroaryl) alkyl and |
| priorityDate | 2005-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.